INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion
16,00 USD
-0,37 %-0,06
8. Nov, 02:00:00 Uhr,
Nasdaq
Kommentare 429
Summer.76,
01.03.2022 19:01 Uhr
0
Intellia Therapeutics Sinks as Patent Ruling Overshadows Crispr Promise
https://www.bloomberg.com/news/articles/2022-03-01/intellia-sinks-after-patent-ruling-overshadows-crispr-promise
• Uncertainty from decision compounds gene-editing stock malaise
• Questions could add fuel to a broader biotech retrenchment
Intellia Therapeutics Inc. fell by the most in more than five years after the gene-editing company suffered a significant legal setback on the same day it unfurled promising early data on its leading drug candidate.
The Cambridge, Massachusetts-based biotechnology company is one of a throng of firms racing to bring new therapies based on the gene-editing technology Crispr to market. On Monday, the U.S. Patent and Trademark Office invalidated a key patent Intellia licensed, casting a cloud of uncertainty over how much the company will be able to profit from the drugs it is developing.
...
The company said in a statement that it is reviewing the patent decision, which it said doesn’t affect any of its ongoing research and development plans.
Intellia has leapfrogged competitors by editing faulty genes inside the human body. On Monday, Intellia showed its experimental Crispr therapy significantly decreased harmful protein in patients with a deadly liver disease.
Nevertheless, investors have become wary of gene-editing stocks in the past year. Intellia shares have shed more than half their market value since hitting a 52-week high in September. Crispr Therapeutics AG has shed nearly two-thirds of its value since a recent peak in June. The company said Monday its programs will continue to advance and aren’t affected by the ruling.
...
S
Steffen2012,
01.03.2022 16:25 Uhr
0
Mhhh wenn ich jetzt alles richtig verstanden habe, muss Intellia jetzt aber einen Lizenzvertrag mit dem Patentinhaber abschließen oder? Ansonsten können sie ja nicht weiter machen. Oder ?
Summer.76,
28.02.2022 22:36 Uhr
0
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
https://www.globenewswire.com/news-release/2022/02/28/2393640/0/en/Intellia-and-Regeneron-Announce-Updated-Phase-1-Data-Demonstrating-a-Single-Dose-of-NTLA-2001-an-Investigational-CRISPR-Therapy-for-Transthyretin-ATTR-Amyloidosis-Resulted-in-Rapid.html
• Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels
• Durable serum TTR reductions observed with patient follow-up ranging from 2 to 12 months
• NTLA-2001 was generally well tolerated at all dose levels
• On track to initiate polyneuropathy dose-expansion cohort (Part 2) in Q1 2022
Summer.76,
24.02.2022 16:51 Uhr
0
https://www.globenewswire.com/news-release/2022/02/24/2391296/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Highlights-Recent-Company-Progress.html
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
Summer.76,
23.02.2022 15:32 Uhr
0
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
https://www.globenewswire.com/news-release/2022/02/23/2390327/0/en/Intellia-Therapeutics-Enters-Lease-Agreement-to-Build-Manufacturing-Facility-for-its-CRISPR-based-Therapies.html
• State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapies
• New facility in Waltham, Massachusetts expected to be operational in 2024
Summer.76,
15.02.2022 15:07 Uhr
0
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
https://finance.yahoo.com/news/intellia-onk-therapeutics-announce-collaboration-123000355.html
Summer.76,
03.02.2022 15:37 Uhr
0
Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
https://www.globenewswire.com/news-release/2022/02/03/2378394/0/en/Intellia-Therapeutics-Announces-Acquisition-of-Rewrite-Therapeutics.html
d
donnralfo,
12.01.2022 22:18 Uhr
0
So langsam wird's wieder interessant. Ein Boden erkennt man nicht...
Summer.76,
31.12.2021 20:46 Uhr
0
https://www.nasdaq.com/articles/intellias-ntla-crispr-therapies-show-promise-amid-competition
Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition
Summer.76,
30.12.2021 19:46 Uhr
0
Ja, das Problem mit der Bewertung findet sich nicht nur hier und deshalb hatte ich nach der Durchbruchsmeldung auch meinen Bestand teils reduziert. Investiert bin ich weiterhin, aber von gerechtfertigt lässt sich natürlich nicht unbedingt sprechen 🙃. Eher davon, dass die Zukunft gehandelt wird.
J
JOEVBLACK,
30.12.2021 17:58 Uhr
0
Summer76, Du scheinst der Firma im Derail zu folgen. Ich überlege einnen Einstieg, finde aber die Bewertung ziemlich astronomisch. Ist sie gerexhtfertigt im Vergleich zu anderen Crispr-cas9 companies ?
Summer.76,
22.11.2021 14:54 Uhr
0
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
https://www.globenewswire.com/news-release/2021/11/22/2338871/0/en/Intellia-Therapeutics-Announces-Expansion-of-Ongoing-Phase-1-Study-of-NTLA-2001-to-Include-Adults-with-Transthyretin-Amyloidosis-with-Cardiomyopathy-ATTR-CM.html
Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy
B
BobbyBobberson,
04.11.2021 13:02 Uhr
0
Intellia accelerates plans to evaluate ATTR amyloidosis candidate in cardiomyopathy
Nov. 04, 2021 7:59 AM ETIntellia Therapeutics, Inc. (NTLA)By: Jonathan M Block, SA News Editor

Meletios Verras/iStock via Getty Images
Intellia Therapeutics (NASDAQ:NTLA) has decided to accelerate plans to evaluate NTLA-2001, its candidate for ATTR amyloidosis, in patients with cardiomyopathy.
The company said that based on an interim dataset, it is seeking regulatory feedback on inclusion of cardiomyopathy patients in its current phase 1 study.
Intellia is eyeing presenting interim data from part 1, a single-ascending dose portion, and to begin part 2, a single-cohort expansion, in Q1 2022.
Elsewhere in the pipeline, the company is planning to begin enrollment in a phase 1 study of NTLA-2002 for hereditary angioedema by the end of the year.
Also, by 1H 2022, Intellia's plans to nominate its first allogeneic development candidate.
In Q3 2021, Intellia's net loss widened ~158% to $71.6M (0.97 per share basic and diluted) due to a significant decline in collaboration revenue and an increase in R&D expenses
B
BobbyBobberson,
04.11.2021 12:49 Uhr
0
Ist natürlich noch nicht wirklich relevant
B
BobbyBobberson,
04.11.2021 12:49 Uhr
0
Intellia Therapeutics EPS misses by $0.11, misses on revenue
Nov. 04, 2021 7:32 AM ETIntellia Therapeutics, Inc. (NTLA)By: Gaurav Batavia, SA News Editor
Intellia Therapeutics (NASDAQ:NTLA): Q3 GAAP EPS of -$0.97 misses by $0.11.
Revenue of $7.21M (-67.5% Y/Y) misses by $1.45M.
Press Release
Cash, cash equivalents and marketable securities were $1,148.7 million as of September 30, 2021, compared to $597.4 million as of December 31, 2020. The increase was driven by net proceeds of $648.3 million from a follow-on offering in Q3 2021, $45.3 million of net proceeds from the Company’s “At the Market” agreement, $40.8 million in proceeds from employee-based stock plans, and $4.2 million of funding for a cost-sharing agreement received from Regeneron. These increases were offset in part by cash used to fund operations of approximately $187.3 million.
Summer.76,
21.10.2021 13:58 Uhr
1
Etwas ausführlicher:
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
https://www.globenewswire.com/news-release/2021/10/21/2318228/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2001-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis.html
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Aktien und Saunaclub alla Luci | ||
2 | BAVARIAN NORDIC Hauptdiskussion | +2,88 % | |
3 | Cleanspark Hauptdiskussion | +4,46 % | |
4 | XIAOMI CORP. CL.B Hauptdiskussion | +3,57 % | |
5 | FREYR BATTERY | ±0,00 % | |
6 | TILRAY INC. CL.2 DL-,0001 Hauptdiskussion | +0,65 % | |
7 | CARNICAL PAIRED Hauptdiskussion | -2,23 % | |
8 | Vulcan Energy Resources Hauptdiskussion | +1,54 % | |
9 | REALTY INCOME Hauptdiskussion | -1,03 % | |
10 | Hexagon Purus | +12,41 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | BAVARIAN NORDIC Hauptdiskussion | +2,88 % | |
2 | Cleanspark Hauptdiskussion | +4,31 % | |
3 | XIAOMI CORP. CL.B Hauptdiskussion | +3,57 % | |
4 | FREYR BATTERY | ±0,00 % | |
5 | TILRAY INC. CL.2 DL-,0001 Hauptdiskussion | ±0,00 % | |
6 | CARNICAL PAIRED Hauptdiskussion | -2,04 % | |
7 | Vulcan Energy Resources Hauptdiskussion | +1,54 % | |
8 | REALTY INCOME Hauptdiskussion | -1,05 % | |
9 | Hexagon Purus | +12,41 % | |
10 | GAMESTOP Hauptdiskussion | +1,43 % | Alle Diskussionen |